NCT06893133Recruiting
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 18 Mar 2025
- Start date
- 8 Apr 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Peking University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06893133
What you commit to
- Study type: Observational
- Planned participants: 110
- From 8 Apr 2025 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.
- Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.
Other
- Other cases considered unsuitable for inclusion by researchers.
Who the study is looking for
- Patients have received neoadjuvant therapy and radical resection (R0).
- Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.
- Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS-WES analysis.
- Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Cancer Hospital & Institute Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.